The proliferation of AD human PC cell lines, LNCaP A., VCaP B. and CWR22Pc C., LNCaP[Src527F] cells D., and the CRPC cell line, CWR22Rv1 E., was assessed (as described in Materials and Methods) in androgen-deprived conditions (Control) vs. DHT treatment (1, 10 or 100 nM). The proliferation of LNCaP[Src527F] cells transduced with empty vector, wt-AR or ARY267,534F was assessed in the presence of 1 nM DHT F. Error bars indicate mean ± SEM. Immunoblots showing total or active (SrcpoY416) in LNCaP or LNCaP[Src527F] cells G., the effect of serum (10% FBS) or Dasatinib (100 nM) on relative Src activation and ARpoY534 levels LNCaP or LNCaP[Src527F] cells H., and the stable expression of ectopic AR-GFP alleles in LNCaP[Src527F] cells, compared to parental AR-positive LNCaP, AR-deficient PC-3, or transiently transfected LNCaP cells (“TX”) I. GAPDH blots were used as protein-loading controls. These blots are representative of at least three independent experiments each.